Ren Xu

4.9k total citations · 1 hit paper
86 papers, 2.7k citations indexed

About

Ren Xu is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Ren Xu has authored 86 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 19 papers in Oncology and 16 papers in Surgery. Recurrent topics in Ren Xu's work include Bone Metabolism and Diseases (11 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Microbial Natural Products and Biosynthesis (8 papers). Ren Xu is often cited by papers focused on Bone Metabolism and Diseases (11 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Microbial Natural Products and Biosynthesis (8 papers). Ren Xu collaborates with scholars based in China, United States and Japan. Ren Xu's co-authors include Matthew B. Greenblatt, Gaofeng Xiong, Jae‐Hyuck Shim, Kim Dremstrup, Chuang Lin, Ning Jiang, Natalie Mrachacz‐Kersting, Dario Farina, Na Li and Alisha R. Yallowitz and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Ren Xu

77 papers receiving 2.7k citations

Hit Papers

Discovery of a periosteal stem cell mediating intramembra... 2018 2026 2020 2023 2018 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ren Xu China 24 989 663 575 559 454 86 2.7k
Xin Huang China 32 1.3k 1.3× 307 0.5× 535 0.9× 381 0.7× 792 1.7× 169 3.1k
Claire M. Edwards United Kingdom 28 917 0.9× 483 0.7× 938 1.6× 253 0.5× 314 0.7× 81 2.8k
Yuan Zhu China 36 1.5k 1.6× 322 0.5× 220 0.4× 223 0.4× 355 0.8× 83 4.0k
Feng Cai China 25 860 0.9× 445 0.7× 163 0.3× 317 0.6× 397 0.9× 81 2.6k
Xi Wang China 31 1.1k 1.1× 1.1k 1.7× 487 0.8× 469 0.8× 378 0.8× 116 3.3k
Ping Gu China 34 1.5k 1.6× 305 0.5× 472 0.8× 490 0.9× 688 1.5× 140 4.0k
Peng Jiang China 33 2.4k 2.5× 370 0.6× 441 0.8× 158 0.3× 1.3k 2.8× 106 3.8k
Nicholas R. Forsyth United Kingdom 30 1.5k 1.5× 810 1.2× 263 0.5× 389 0.7× 576 1.3× 102 3.8k

Countries citing papers authored by Ren Xu

Since Specialization
Citations

This map shows the geographic impact of Ren Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ren Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ren Xu more than expected).

Fields of papers citing papers by Ren Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ren Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ren Xu. The network helps show where Ren Xu may publish in the future.

Co-authorship network of co-authors of Ren Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Ren Xu. A scholar is included among the top collaborators of Ren Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ren Xu. Ren Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Ning, Xiumei Luo, Rui Huang, et al.. (2025). Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites. Journal of Orthopaedic Translation. 55. 280–292.
2.
3.
Zhang, Fan, Yuan Wang, Chunjie Wang, et al.. (2024). The ESCRT protein CHMP5 restricts bone formation by controlling endolysosome-mitochondrion-mediated cell senescence. eLife. 13. 1 indexed citations
4.
Xing, Na, Yingkun Zhang, Zan Li, et al.. (2024). Highly Multiplexed, Efficient, and Automated Single‐Cell MicroRNA Sequencing with Digital Microfluidics. (Small Methods 3/2024). Small Methods. 8(3). 1 indexed citations
5.
Zhang, Long, Weibin Li, Fan Shi, et al.. (2024). Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling. Chemico-Biological Interactions. 394. 110968–110968. 2 indexed citations
6.
Chen, Yu, Long Zhang, Jie Han, et al.. (2024). Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Advanced Science. 11(18). e2303752–e2303752. 16 indexed citations
7.
Xu, Ren. (2024). Impacts of immune microenvironment on musculoskeletal health. SHILAP Revista de lepidopterología. 4(2). 2 indexed citations
8.
Wang, Haosheng, et al.. (2024). Development and validation of a nomogram for predicting mortality in patients with acute severe traumatic brain injury: A retrospective analysis. Neurological Sciences. 45(10). 4931–4956. 1 indexed citations
9.
Chen, Yingwen, Na Xing, Yingkun Zhang, et al.. (2023). Highly Multiplexed, Efficient, and Automated Single‐Cell MicroRNA Sequencing with Digital Microfluidics.. Small Methods. 8(3). e2301250–e2301250. 8 indexed citations
10.
Zhou, Taifeng, Yu Chen, Zhiheng Liao, et al.. (2023). Spatiotemporal Characterization of Human Early Intervertebral Disc Formation at Single‐Cell Resolution. Advanced Science. 10(14). e2206296–e2206296. 31 indexed citations
11.
Li, Xuedong, Xiaohong Chen, Yu Chen, et al.. (2023). Phosphatidyl Inositol 3-Kinase (PI3K)-Inhibitor CDZ173 protects against LPS-induced osteolysis. Frontiers in Pharmacology. 13. 1021714–1021714. 1 indexed citations
12.
Yin, Pengbin, Ming Chen, Lin Yuan, et al.. (2023). Deciphering Immune Landscape Remodeling Unravels the Underlying Mechanism for Synchronized Muscle and Bone Aging. Advanced Science. 11(5). e2304084–e2304084. 12 indexed citations
14.
Pan, Yi, et al.. (2021). Test Case Prioritization Based on Artificial Immune Algorithm. Tehnicki vjesnik - Technical Gazette. 28(6). 1 indexed citations
15.
Xu, Jun, Shoufang Qu, Nan Sun, et al.. (2020). Construction of a reference material panel for detecting KRAS / NRAS / EGFR / BRAF / MET mutations in plasma ctDNA. Journal of Clinical Pathology. 74(5). 314–320. 7 indexed citations
16.
Kim, Jung‐Min, Kwang Hwan Park, Xianpeng Ge, et al.. (2020). A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation. Nature Communications. 11(1). 2289–2289. 70 indexed citations
17.
Bok, Seoyeon, Dong Yeon Shin, Alisha R. Yallowitz, et al.. (2020). MEKK2 mediates aberrant ERK activation in neurofibromatosis type I. Nature Communications. 11(1). 5704–5704. 13 indexed citations
18.
Xu, Ren, et al.. (2019). Co-occurrence of IPMN and malignant IPNB complicated by a pancreatobiliary fistula: A case report and review of the literature. World Journal of Clinical Cases. 7(1). 102–108. 15 indexed citations
19.
Xu, Ren, Ning Jiang, Chuang Lin, et al.. (2014). Enhanced Low-Latency Detection of Motor Intention From EEG for Closed-Loop Brain-Computer Interface Applications. IEEE Transactions on Biomedical Engineering. 61(2). 288–296. 163 indexed citations
20.
Liao, Zhuan, Joseph W. Leung, Xiao Zhang, et al.. (2008). How Safe and Successful Are Live Demonstrations of Therapeutic ERCP? A Large Multicenter Study. The American Journal of Gastroenterology. 104(1). 47–52. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026